Search

Displaying results 2491 - 2500 of 7502 in total
  1. Drug

    Poa compressa pollen

    go.drugbank.com/drugs/DB10713
    Approved

    Poa compressa pollen is the pollen of the Poa compressa plant. Poa compressa pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Inland Grasses, Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  2. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes. … [A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act.

  3. Drug

    Cyclophosphamide

    go.drugbank.com/drugs/DB00531
    ApprovedInvestigational

    Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide.

    Synonyms: N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
  4. Drug

    Menthyl salicylate

    go.drugbank.com/drugs/DB11201
    Approved

    This product is used to treat minor aches and pains of the muscles/joints (e.g., arthritis, backache, sprains) [L2810].

    Categories: Anti-Inflammatory Agents, Non-Steroidal
  5. Drug

    Cholic Acid

    go.drugbank.com/drugs/DB02659
    ApprovedInvestigational

    [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single

  6. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.

  7. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells [A40022].

    Synonyms: 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
  8. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.

  9. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.

  10. Drug

    Sodium borate

    go.drugbank.com/drugs/DB14505
    Approved